Sun Pharmaceutical has announced the release of Unloxcyt™ (Cosibelimab-IPDL), a new therapeutic option for patients diagnosed with advanced cutaneous squamous cell carcinoma. This launch marks a significant addition to the company's oncology portfolio, providing healthcare professionals with an innovative treatment alternative for this form of skin cancer.

Product Overview

Unloxcyt™ represents Sun Pharmaceutical's latest entry into the specialized oncology market. The treatment is specifically indicated for advanced cutaneous squamous cell carcinoma, a type of skin cancer that requires targeted therapeutic intervention.

Market Impact

The launch of Unloxcyt™ strengthens Sun Pharmaceutical's position in the oncology segment, demonstrating the company's commitment to developing treatments for complex medical conditions. This addition to their therapeutic portfolio provides healthcare providers with another option for managing patients with advanced cutaneous squamous cell carcinoma.

The introduction of this specialized oncology treatment reflects Sun Pharmaceutical's strategic focus on addressing unmet medical needs in cancer care, particularly in the dermatological oncology space.

Life Insurance Corporation of India (LIC) has increased its shareholding in Sun Pharmaceutical Industries Limited, crossing the 5% threshold that triggers mandatory disclosure under SEBI regulations. The state-owned insurance company acquired additional shares through market purchase on January 13, 2026.

Shareholding Details

LIC's shareholding movement shows a strategic increase in its position in the pharmaceutical major. The transaction details are presented below:

Regulatory Compliance

The disclosure was made under Regulation 29(1) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. This regulation mandates disclosure when any entity's shareholding in a listed company exceeds 5% or increases/decreases by 2% or more.

Transaction Specifics

LIC acquired 2,02,500 shares carrying voting rights through market purchase, representing 0.008% of Sun Pharmaceutical's total share capital. The acquisition was completed on January 13, 2026, and the formal disclosure was submitted to the company and stock exchanges on January 14, 2026.

The insurance corporation confirmed it does not belong to the promoter or promoter group of Sun Pharmaceutical Industries Limited. LIC's investment falls under its regular portfolio management activities as India's largest life insurance company.

Market Context

Sun Pharmaceutical Industries Limited maintains its equity share capital at 2,39,93,34,970 shares, with no changes reported before or after LIC's acquisition. The company's shares are listed on both NSE and BSE, providing liquidity for institutional investors like LIC to adjust their positions.

This acquisition reflects LIC's continued interest in the pharmaceutical sector, with Sun Pharmaceutical being one of India's leading pharmaceutical companies. The formal disclosure process ensures transparency in substantial shareholding changes for market participants and regulatory authorities.